Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers
Completed
Azevan Pharmaceuticals
Phase 1
This is a multiple dose clinical study to be conducted with SRX246 capsules to determine the
safety, tolerability and pharmacokinetics of the drug over a 14 day dosing period.
Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
Completed
Azevan Pharmaceuticals
Phase 1/Phase 2
This study is designed to explore the safety and tolerability, and to compare the activity of
SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED).
Adult Male and Female subjects with a current diagnosis of IED will be enrolled. After a
two-week baseline lead-in phase, study subjects who continue to meet enrollment criteria will
be randomized to either SRX246 or Placebo treatment groups.
Study subjects will be examined and asked to answer questionnaires at weekly scheduled visits
throughout the trial. The study results will be determined based on any changes observed over
the study period.
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
Completed
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 2
This study evaluates the tolerability, safety and activity of SRX246 in the treatment of
irritability in patients with Huntington's disease. Two-thirds of all participants will
receive SRX246, while the other third will receive a placebo.
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
Completed
NeuroNEXT Network
Phase 2
This study evaluates the tolerability, safety and activity of SRX246 in the treatment of
irritability in patients with Huntington's disease. Two-thirds of all participants will
receive SRX246, while the other third will receive a placebo.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.